Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:57:44.932Z.
Calculation as of: 2026-10-06T14:57:44.932Z.
Quote observation: 2026-10-06T14:55:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.46B
EV/EBITDA Ratio
9.02x
TTM Avg
18.38x
3Y Avg
16.03x
5Y Avg
16.85x
Market Cap
$1.44B
EV/EBITDA Ratio
11.59x
TTM Avg
34.83x
3Y Avg
34.83x
5Y Avg
32.76x
Market Cap
$1.51B
EV/EBITDA Ratio
72.64x
TTM Avg
329.18x
3Y Avg
230.60x
5Y Avg
237.22x
Market Cap
$1.52B
EV/EBITDA Ratio
4.31x
TTM Avg
3.71x
3Y Avg
17.44x
5Y Avg
17.91x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.46B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 9.02x | 18.38x | 16.03x | 16.85x |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 26.86x | 16.63x | 66.61x | 73.09x |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 11.59x | 34.83x | 34.83x | 32.76x |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 72.64x | 329.18x | 230.60x | 237.22x |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 4.31x | 3.71x | 17.44x | 17.91x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2025-08-12 | 6.26x |
| 2025-08-11 | 6.04x |
| 2025-08-08 | 5.77x |
| 2025-08-07 | 5.91x |
| 2025-08-06 | 6.68x |
| 2025-08-05 | 6.89x |
| 2025-08-04 | 7.50x |
| 2025-08-01 | 7.21x |
| 2025-07-31 | 7.09x |
| 2025-07-30 | 7.71x |
| 2025-07-29 | 7.91x |
| 2025-07-28 | 8.42x |
| 2025-07-25 | 8.79x |
| 2025-07-24 | 8.49x |
| 2025-07-23 | 9.47x |
| 2025-07-22 | 8.89x |
| 2025-07-21 | 8.66x |
| 2025-07-18 | 9.58x |
| 2025-07-17 | 8.99x |
| 2025-07-16 | 8.33x |
| 2025-07-15 | 8.13x |
| 2025-07-14 | 7.91x |
| 2025-07-11 | 7.34x |
| 2025-07-10 | 7.82x |
| 2025-07-09 | 7.36x |
| 2025-07-08 | 7.35x |
| 2025-07-07 | 4.93x |
| 2025-07-03 | 4.42x |
| 2025-07-02 | 4.71x |
| 2025-07-01 | 4.55x |
| 2025-06-30 | 5.05x |
| 2025-06-27 | 4.94x |
| 2025-06-26 | 5.44x |
| 2025-06-25 | 4.34x |
| 2025-06-24 | 3.45x |
| 2025-06-23 | 3.78x |
| 2025-06-20 | 4.15x |
| 2025-06-18 | 4.22x |
| 2025-06-17 | 5.15x |
| 2025-06-16 | 5.91x |
| 2025-06-13 | 5.98x |
| 2025-06-12 | 6.10x |
| 2025-06-11 | 5.47x |
| 2025-06-10 | 5.54x |
| 2025-06-09 | 5.49x |
| 2025-06-06 | 5.59x |
| 2025-06-05 | 5.93x |
| 2025-06-04 | 6.37x |
| 2025-06-03 | 6.19x |
| 2025-06-02 | 4.91x |
| 2025-05-30 | 3.19x |
| 2025-05-29 | 4.97x |
| 2025-05-28 | 4.40x |
| 2025-05-27 | 4.17x |
| 2025-05-23 | 3.41x |
| 2025-05-22 | 3.32x |
| 2025-05-21 | 3.61x |
| 2025-05-20 | 3.27x |
| 2025-05-19 | 2.94x |
| 2025-05-16 | 2.57x |
| 2025-05-15 | 2.57x |
| 2025-05-14 | 3.72x |
| 2025-05-13 | 4.30x |
| 2025-05-12 | 4.49x |
| 2025-05-09 | 4.12x |
| 2025-05-08 | 4.41x |
| 2025-05-07 | 4.03x |
| 2025-05-06 | 3.76x |
| 2025-05-05 | 4.70x |
| 2025-05-02 | 5.01x |
| 2025-05-01 | 4.82x |
| 2025-04-30 | 3.86x |
| 2025-04-29 | 3.53x |
| 2025-04-28 | 3.23x |
| 2025-04-25 | 3.11x |
| 2025-04-24 | 2.74x |
| 2025-04-23 | 4.07x |
| 2025-04-22 | 4.30x |
| 2025-04-21 | 3.77x |
| 2025-04-17 | 3.25x |
| 2025-04-16 | 3.09x |
| 2025-04-15 | 3.03x |
| 2025-04-14 | 3.32x |
| 2025-04-11 | 2.84x |
| 2025-04-10 | 2.67x |
| 2025-04-09 | 2.94x |
| 2025-04-08 | 2.65x |
| 2025-04-07 | 3.62x |
| 2025-04-04 | 3.73x |
| 2025-04-03 | 3.91x |
| 2025-04-02 | 4.66x |
| 2025-04-01 | 4.33x |
| 2025-03-31 | 6.07x |
| 2025-03-28 | 6.33x |
| 2025-03-27 | 6.24x |
| 2025-03-26 | 5.91x |
| 2025-03-25 | 6.47x |
| 2025-03-24 | 6.62x |
| 2025-03-21 | 6.15x |
| 2025-03-20 | 6.68x |
| 2025-03-19 | 6.80x |
| 2025-03-18 | 6.74x |
| 2025-03-17 | 6.38x |
| 2025-03-14 | 6.05x |
| 2025-03-13 | 6.25x |
| 2025-03-12 | 6.25x |
| 2025-03-11 | 6.20x |
| 2025-03-10 | 6.56x |
| 2025-03-07 | 6.71x |
| 2025-03-06 | 6.53x |
| 2025-03-05 | 6.62x |
| 2025-03-04 | 6.60x |
| 2025-03-03 | 6.09x |
| 2025-02-28 | 6.85x |
| 2025-02-27 | 7.17x |
| 2025-02-26 | 6.51x |
| 2025-02-25 | 5.78x |
| 2025-02-24 | 5.94x |
| 2025-02-21 | 6.76x |
| 2025-02-20 | 6.82x |
| 2025-02-19 | 7.07x |
| 2025-02-18 | 7.22x |
| 2025-02-14 | 6.71x |
| 2025-02-13 | 6.27x |
| 2025-02-12 | 6.69x |
| 2025-02-11 | 7.01x |
| 2025-02-10 | 7.33x |
| 2025-02-07 | 7.60x |
| 2025-02-06 | 7.35x |
| 2025-02-05 | 7.24x |
| 2025-02-04 | 7.51x |
| 2025-02-03 | 8.64x |
| 2025-01-31 | 9.26x |
